Physician profile
Christopher Stephens
NPI 1265029607
$1,651.31
in general payments reported to CMS, 2019-2025
17 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $444 · 2023: $240 · 2024: $497 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.90 | 2021-2025 | |
| Indivior INC. | $158.96 | 2021-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $147.90 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $143.22 | 2021-2024 | Rexulti |
| Braeburn INC. | $128.50 | 2023-2025 | Brixadi |
| Alkermes, INC. | $106.90 | 2022-2024 | Vivitrol, Vivitrol |
| Janssen Pharmaceuticals, INC | $97.65 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $94.01 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $90.85 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $77.64 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.53 | 2021-2024 | Caplyta |
| Orexo US, INC. | $35.84 | 2023 | Zubsolv |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.70 | 2025 | |
| Tris Pharma INC | $20.91 | 2024 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $16.94 | 2025 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $14.01 | 2022 | |
| Lundbeck LLC | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.